Jaiman Manasi 4

What Happened
Jaiman Manasi, Chief Medical Officer of Aardvark Therapeutics (AARD), received a grant of 70,549 derivative shares on February 9, 2026. The reported price is $0.00, so there was no cash paid or received at the time of the grant. This transaction is an award/grant (derivative security), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-09; Form 4 filed 2026-02-11 (filed within the typical 2-business-day window).
• Transaction type/code: A (award/grant) of derivative securities.
• Shares involved: 70,549 derivative shares granted at $0.00 (no immediate proceeds).
• Vesting: Per footnote — 1/4 vests on Feb 9, 2027, then 1/48 vests monthly thereafter, contingent on continued service.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• No indication this was a 10b5-1 sale, cashless exercise, gift, or tax-withholding event in the provided details.

Context
This is a standard equity compensation grant tied to continued service (vesting over time). Because it’s a derivative award with a vesting schedule, there’s no immediate sale or market impact from this filing. Such grants are common as part of executive compensation and do not by themselves indicate a buy/sell signal.